MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.dld.2015.12.013

Медицинская библиотека · Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2016

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.

Ruszniewski Philippe, Valle Juan W, Lombard-Bohas Catherine, Cuthbertson Daniel J, Perros Petros, Holubec Luboš, Delle Fave Gianfranco, Smith Denis, Niccoli Patricia, Maisonobe Pascal, Atlan Philippe, Caplin Martyn E, SYMNET study group

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse.

AIM: To evaluate the effect of lanreotide on patient-reported outcomes (PROs) with carcinoid syndrome.

METHODS

This was an international, open-label, observational study of adults with neuroendocrine tumours and history of diarrhoea, receiving lanreotide for >3 months for relief of carcinoid syndrome symptoms. The primary PRO measure was satisfaction with diarrhoea control. Secondary PRO measures included severity, change in symptoms and impact on daily life of diarrhoea; and patient satisfaction with flushing control.

RESULTS

Of 273 patients enrolled, 76% were 'completely' or 'rather' satisfied with diarrhoea control; 79% reported improvement in diarrhoea with lanreotide. The proportion of patients with 'mild', 'minimal', or 'no diarrhoea' increased from 33% before treatment to 75% during treatment; 75% were unconcerned about the impact of diarrhoea on daily life. Satisfaction with flushing control amongst patients with significant flushing at treatment initiation was 73%.

CONCLUSIONS

Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome (ClinicalTrials.gov: NCT01234168).

Для цитирования: Ruszniewski Philippe, Valle Juan W, Lombard-Bohas Catherine, Cuthbertson Daniel J, Perros Petros, Holubec Luboš, Delle Fave Gianfranco, Smith Denis, Niccoli Patricia, Maisonobe Pascal, Atlan Philippe, Caplin Martyn E, SYMNET study group. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2016. DOI: 10.1016/j.dld.2015.12.013.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.